OA10419A - Cisapride extended release oral compositions - Google Patents

Cisapride extended release oral compositions Download PDF

Info

Publication number
OA10419A
OA10419A OA70001A OA70001A OA10419A OA 10419 A OA10419 A OA 10419A OA 70001 A OA70001 A OA 70001A OA 70001 A OA70001 A OA 70001A OA 10419 A OA10419 A OA 10419A
Authority
OA
OAPI
Prior art keywords
cisapride
extended release
release formulation
weight
tartrate
Prior art date
Application number
OA70001A
Other languages
English (en)
Inventor
Eugene Marie Jozef
Paul Marie Victor Gilis
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of OA10419A publication Critical patent/OA10419A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cereal-Derived Products (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
OA70001A 1994-11-02 1997-05-02 Cisapride extended release oral compositions OA10419A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94203184 1994-11-02

Publications (1)

Publication Number Publication Date
OA10419A true OA10419A (en) 2001-12-06

Family

ID=8217338

Family Applications (1)

Application Number Title Priority Date Filing Date
OA70001A OA10419A (en) 1994-11-02 1997-05-02 Cisapride extended release oral compositions

Country Status (29)

Country Link
US (2) US6153623A (pl)
EP (1) EP0789572A1 (pl)
JP (1) JP3182423B2 (pl)
KR (1) KR100255521B1 (pl)
AP (1) AP658A (pl)
AR (1) AR001765A1 (pl)
AU (1) AU704284B2 (pl)
BG (1) BG63244B1 (pl)
BR (1) BR9509565A (pl)
CA (1) CA2203663C (pl)
CZ (1) CZ287844B6 (pl)
EE (1) EE03510B1 (pl)
FI (1) FI971856L (pl)
HR (1) HRP950539A2 (pl)
HU (1) HUT77887A (pl)
IL (1) IL115843A0 (pl)
MY (1) MY113092A (pl)
NO (1) NO312538B1 (pl)
NZ (1) NZ295166A (pl)
OA (1) OA10419A (pl)
PL (1) PL181470B1 (pl)
RO (1) RO116042B1 (pl)
RU (1) RU2143890C1 (pl)
SK (1) SK54297A3 (pl)
TR (1) TR199501351A2 (pl)
TW (1) TW466114B (pl)
UA (1) UA50721C2 (pl)
WO (1) WO1996014070A1 (pl)
ZA (1) ZA959221B (pl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release
CA2232489A1 (en) * 1995-12-01 1997-06-12 Janssen Pharmaceutica N.V. Cisapride sustained release
DE69713948D1 (de) * 1996-04-23 2002-08-22 Janssen Pharmaceutica Nv Rasch-freisetzende pH-unabhängige feste Dosisformen enthaltend Cisaprid
EP0951278A2 (en) * 1997-01-03 1999-10-27 ELAN CORPORATION, Plc Sustained release cisapride mini-tablet formulation
JP2002504107A (ja) * 1997-06-11 2002-02-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （＋）−または（−）−シサプリドの即時放出性ｐＨ非依存的固形投薬剤形
TW407058B (en) 1998-07-17 2000-10-01 Dev Center Biotechnology Oral cisapride dosage forms with an extended duration
CO5140079A1 (es) * 1998-10-14 2002-03-22 Novartis Ag Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo
EP1169024B1 (en) 1999-03-31 2005-12-21 Janssen Pharmaceutica N.V. Pregelatinized starch in a controlled release formulation
EP1060743A1 (en) * 1999-06-17 2000-12-20 Development Center For Biotechnology Oral cisapride dosage forms with an extended duration
CZ20021076A3 (cs) * 1999-09-28 2002-08-14 Panacea Biotec Limited Prostředky s kontrolovaným uvolňováním obsahující nimesulid
ATE361060T1 (de) * 2000-09-29 2007-05-15 Solvay Pharm Bv Ionenstärkenunabhängige pharmazeutische formulierung mit verzögerter freisetzung
DE60228939D1 (de) * 2002-05-21 2008-10-30 Watson Lab Inc Pharmazeutische Zusammensetzung mit verzögerter Freisetzung
EP2005946B1 (en) 2006-04-12 2015-11-18 Nippon Soda Co., Ltd. Method for producing extended release tablet
RU2356532C2 (ru) * 2007-06-01 2009-05-27 Открытое Акционерное Общество "Отечественные Лекарства" Фармацевтическая композиция проксодолола с контролируемым высвобождением
WO2010099508A1 (en) 2009-02-26 2010-09-02 Theraquest Biosciences, Inc. Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057525A (en) * 1981-10-01 1991-10-15 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl) benzamide derivatives
CA1183847A (en) * 1981-10-01 1985-03-12 Georges Van Daele N-(3-hydroxy-4-piperidinyl)benzamide derivatives
ES2124303T3 (es) * 1992-03-25 1999-02-01 Depomed Inc Formas de dosificacion de farmacos orales de liberacion retardada a base de hidroxietilcelulosa.
EP1145715A3 (en) * 1992-07-07 2004-05-19 Sepracor Inc. Methods of using (-) cisapride for the treatment of gastro-esophageal reflux disease and other disorders
ZA959221B (en) * 1994-11-02 1997-04-30 Janssen Pharmaceutica Nv Cisapride extended release

Also Published As

Publication number Publication date
AP658A (en) 1998-08-17
SK54297A3 (en) 1997-10-08
CA2203663A1 (en) 1996-05-17
AU3844795A (en) 1996-05-31
AR001765A1 (es) 1997-12-10
RU2143890C1 (ru) 2000-01-10
EE9700105A (et) 1997-12-15
CA2203663C (en) 2002-04-30
MY113092A (en) 2001-11-30
EE03510B1 (et) 2001-10-15
NO312538B1 (no) 2002-05-27
TW466114B (en) 2001-12-01
BG63244B1 (bg) 2001-07-31
CZ124497A3 (en) 1997-08-13
NO971832L (no) 1997-04-21
KR100255521B1 (ko) 2000-05-01
US6153623A (en) 2000-11-28
TR199501351A2 (tr) 1996-06-21
NO971832D0 (no) 1997-04-21
JPH09511760A (ja) 1997-11-25
BG101401A (bg) 1997-12-30
AP9700969A0 (en) 1997-04-30
PL181470B1 (pl) 2001-07-31
NZ295166A (en) 1999-03-29
FI971856A0 (fi) 1997-04-30
AU704284B2 (en) 1999-04-15
US6274599B1 (en) 2001-08-14
ZA959221B (en) 1997-04-30
CZ287844B6 (en) 2001-02-14
HUT77887A (hu) 1998-09-28
MX9703249A (es) 1997-07-31
JP3182423B2 (ja) 2001-07-03
FI971856A7 (fi) 1997-04-30
EP0789572A1 (en) 1997-08-20
FI971856L (fi) 1997-04-30
WO1996014070A1 (en) 1996-05-17
BR9509565A (pt) 1997-09-16
PL319948A1 (en) 1997-09-01
HRP950539A2 (en) 1997-08-31
RO116042B1 (ro) 2000-10-30
IL115843A0 (en) 1996-01-31
UA50721C2 (uk) 2002-11-15

Similar Documents

Publication Publication Date Title
EP2588086B1 (en) Pharmaceutical compositions comprising 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactate monohydrate.
OA10419A (en) Cisapride extended release oral compositions
EP2079446B1 (en) Paliperidone sustained release formulation
US20090317473A1 (en) Controlled-release formulations, method of manufacture, and use thereof
JP7117975B2 (ja) テネリグリプチン含有医薬組成物、テネリグリプチン含有医薬組成物の製造方法、テネリグリプチン含有錠剤及びテネリグリプチン含有錠剤の製造方法
US20030190353A1 (en) Low water-soluble venlafaxine salts
US20170202819A1 (en) Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
EP2468268B1 (en) Combination composition of vildagliptin and gliclazide
EP4008317A1 (en) Solid pharmaceutical formulations of amorphous dapagliflozin
CA2374039C (en) Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
US20130172411A1 (en) Stable pharmaceutical compositions comprising fesoterodine
KR20190089758A (ko) 미라베그론 또는 이의 약제학적으로 허용가능한 염을 함유하는 지속 방출 제제
KR20200078146A (ko) 내산성이 우수한 탐수로신 염산염 함유 제약 조성물 및 이의 제조방법
EP4262759A1 (en) Immediate release solid dosage form comprising teriflunomide and method of preparation thereof
JP4808612B2 (ja) アルキレンジオキシベンゼン誘導体を含む経口投与用組成物
EP1815850B1 (en) Controlled release formulation of divalproic acid and its derivatives
US20070160667A1 (en) Controlled release formulation of divalproex sodium
EP2736496B1 (en) Pharmaceutical composition containing an antimuscarinic agent and method for the preparation thereof
US20080008754A1 (en) Pharmaceutical Compositions Comprising (+)-(2S,3S)-2-(3-Chlorophenyl)-3,5,5-Trimethyl-2-Morpholinol
WO2025106043A1 (en) A bilayer tablet composition comprising dapagliflozin and metformin
EP4491175A1 (en) A solid oral composition of ruxolitinib
AU2006335344A1 (en) Controlled release formulation of divalproic acid and its derivatives
MXPA97003249A (en) Oral compositions of extended release of cisapr
KR20230092881A (ko) 프탈라지논 유도체를 포함하는 약제학적 조성물
US20130267560A1 (en) Sustained release pharmaceutical compositions of donepezil